Annual report pursuant to Section 13 and 15(d)

Note Payable

v3.22.0.1
Note Payable
 12 Months Ended
Nov. 30, 2021
Debt Disclosure [Abstract]  
Note Payable

NOTE 4 – NOTE PAYABLE

On May 20, 2016, the Company entered into a Credit Agreement (“Agreement”) with Texas Capital Bank, National Association (“TCB”) for a term loan of $8.0 million in senior credit facilities. The proceeds of the term loan were used by the Company to fund repurchases of the Company’s common stock. Subject to the terms of the Agreement, on May 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated May 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable monthly with a maturity date of July 2021 extended to June 2022 with Second Amendment. On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an additional advance to the Company in principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The additional proceeds of the term loan were used by the Company to fund the extinguishment of revenue sharing agreements. On June 11, 2018, the Company entered into a Second Amendment to Credit Agreement with TCB. Pursuant to the terms of the Second Amendment to Credit Agreement, TCB increased the current outstanding principal amount of the loan from TCB by $9,000,000 to finance a portion of the purchase price of the Cord:Use Purchase. In connection therewith, Cryo-Cell executed and delivered to TCB a Second Amended and Restated Promissory Note, in the principal amount of $15,500,000. As of November 30, 2021, and November 30, 2020, the Company paid interest of $118,117 and $310,364, respectively, which is reflected in interest expense on the accompanying consolidated statements of comprehensive income.

Collateral of the term and subordinated loans includes all money, securities and property of the Company.

The Company incurred debt issuance costs related to the term and subordinated loans in the amount of $548,085 which is recorded as a direct reduction of the carrying amount of the note payable and amortized over the life of the loan. As of November 30, 2021, and November 30, 2020, $56,851 and $85,062, respectively, of the debt issuance costs were amortized and are reflected in interest expense on the accompanying consolidated statements of comprehensive income.

As of November 30, 2021, and November 30, 2020, the note payable obligation was as follows:

 

 

 

November 30, 2021

 

 

November 30, 2020

 

Note payable

 

$

1,908,433

 

 

$

6,008,433

 

Unamortized debt issuance costs

 

 

(10,368

)

 

 

(67,219

)

Net note payable

 

$

1,898,065

 

 

$

5,941,214

 

Current portion of note payable

 

$

1,898,065

 

 

$

3,100,000

 

Long-term note payable, net of debt issuance costs

 

 

—

 

 

 

2,841,214

 

Total

 

$

1,898,065

 

 

$

5,941,214

 

 

Interest expense on the note payable for the years ended November 30, 2021 and November 30, 2020 was as follows:

 

 

 

November 30, 2021

 

 

November 30, 2020

 

Interest expense on notes payable

 

$

118,117

 

 

$

310,364

 

Debt issuance costs

 

 

56,851

 

 

 

85,062

 

Total interest expense

 

$

174,968

 

 

$

395,426